Please login to the form below

Not currently logged in
Email:
Password:

Lexicon Pharmaceuticals

This page shows the latest Lexicon Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting

Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting

US-based Lexicon Pharmaceuticals has announced further analyses on the cardiovascular benefits of its first-in-class candidate, sotagliflozin, at the European Society of Cardiology annual meeting. ... Last month Lexicon announced revenues for the three

Latest news

  • Sanofi exits Zynquista alliance with Lexicon Sanofi exits Zynquista alliance with Lexicon

    Will pay $260m to end collaboration. Following rejection from the FDA earlier this year, Sanofi has agreed to pay Lexicon Pharmaceuticals $260m to end the alliance formed to develop and ... for demonstrating cardiovascular and renal benefits,” said

  • Ipsen searches for new CEO after splitting top roles Ipsen searches for new CEO after splitting top roles

    Ipsen licenses the drug from Lexicon Pharmaceuticals and has rights outside the US and Japan.

  • Sanofi and Lexicon collaborate on new medication for diabetes Sanofi and Lexicon collaborate on new medication for diabetes

    Plan to develop new investigational drugsotagliflozin. Sanofi and Lexicon Pharmaceuticals have agreed to collaborate in the development and commercialisation of sotagliflozin, an investigational new drug for diabetes. ... Pascale Witz, executive VP at

  • Lexicon announces IBS trial results

    Lexicon Pharmaceuticals’ TPH inhibitor LX1031 has been shown in a phase II trial to be well tolerated and provide clinical benefit to patients with irritable bowel syndrome. ... The biopharmaceutical company Lexicon Pharmaceuticals has announced the

  • Lexicon reveals two agreements to fund long-term drug development

    Lexicon Pharmaceuticals has entered into a major financing agreement with Invus Group to help fund the company's transition into an integrated biopharmaceutical company. ... US biopharmaceutical company Lexicon Pharmaceuticals has entered into a major

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    Licensor Acquired/ Licensee Acquirer. Product/ Technology. Deal Type. Headline ($m). Selexys Pharmaceuticals/ Novartis. ... Strategic alliance, options. 122.7 per. BMS/ Lexicon Pharmaceuticals. BMS-986176 for neutopathic pain (pc) plus other small

  • Deal Watch November 2015 Deal Watch November 2015

    Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    For multivalent MVA-BN Filovirus vaccine. 187. Lexicon Pharmaceuticals/Ipsen. Licence [B]. Telotristat etiprate in P3 for carcinoid syndrome.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....